⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19068316 | 1.00 | — | — | |
| SCHEMBL15025160 | 1.00 | — | — | |
| SCHEMBL1699657 | 1.00 | — | — | |
| SCHEMBL13164323 | 0.87 | — | — | |
| SCHEMBL769531 | 0.87 | — | — | |
| SCHEMBL15034303 | 0.85 | — | — | |
| SCHEMBL10076032 | 0.85 | — | — | |
| SCHEMBL10072494 | 0.84 | — | — | |
| SCHEMBL2614697 | 0.83 | — | — | |
| SCHEMBL1699642 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926556-B2 | Linkage modified oligomeric compounds | IONIS PHARMACEUTICALS, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9752142-B2 | Gapped oligomeric compounds comprising 5′-modified deoxyribonucleosides in the gap and uses thereof | IONIS PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170130224-A1 | LINKAGE MODIFIED GAPPED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170044526-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
| US-9005906-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140315979-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140309279-A1 | GAPPED OLIGOMERIC COMPOUNDS COMPRISING 5'-MODIFIED DEOXYRIBONUCLEOSIDES IN THE GAP AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140303235-A1 | LINKAGE MODIFIED GAPPED OLIGOMERIC COMPOUNDS AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-8796437-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130211064-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8440803-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120071645-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-8088904-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |